Academic literature on the topic 'Hepatitis C chronic/pathology'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hepatitis C chronic/pathology.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Hepatitis C chronic/pathology"
Fiel, M. Isabel. "Pathology of Chronic Hepatitis B and Chronic Hepatitis C." Clinics in Liver Disease 14, no. 4 (2010): 555–75. http://dx.doi.org/10.1016/j.cld.2010.07.001.
Full textKage, M., T. Fujisawa, K. Shiraki, et al. "Pathology of chronic hepatitis C in children." Hepatology 26, no. 3 (1997): 771–75. http://dx.doi.org/10.1002/hep.510260333.
Full textPHULPOTO, JAVED AHMED. "CHRONIC HEPATITIS C-INFECTED PATIENTS;." Professional Medical Journal 20, no. 01 (2012): 068–71. http://dx.doi.org/10.29309/tpmj/2013.20.01.478.
Full textTsvetkov, V. V., I. I. Tokin, and S. A. Pozdnjakova. "Clinical epidemiology of extrahepatic manifestations of chronic hepatitis C virus infection." Medical Council, no. 21 (January 28, 2020): 248–53. http://dx.doi.org/10.21518/2079-701x-2019-21-248-253.
Full textStahl, Jurgen. "Yet another cause for granulomatous hepatitis: chronic hepatitis C." Advances in Anatomic Pathology 8, no. 1 (2001): 48–49. http://dx.doi.org/10.1097/00125480-200101000-00010.
Full textMarinelli, RMA, M. Delle Monache, R. Gerardi, et al. "Liver Pathology in Cytomegalovirus Infection Associated with Hepatitis B Virus." Journal of International Medical Research 21, no. 3 (1993): 154–57. http://dx.doi.org/10.1177/030006059302100306.
Full textNikonorova, Marina A., N. S. Lubskaya, E. V. Volchkova, E. A. Nemilostiva, and O. I. Matros. "VARIANTS OF THYROID GLAND PATHOLOGY IN CHRONIC HEPATITIS C PATIENTS." Epidemiology and Infectious Diseases 22, no. 4 (2017): 172–77. http://dx.doi.org/10.17816/eid40958.
Full text&NA;. "The natural history of chronic hepatitis C." Advances in Anatomic Pathology 4, no. 6 (1997): 380. http://dx.doi.org/10.1097/00125480-199711000-00029.
Full textBanner, B. F., C. Allan, L. Savas, S. Baker, G. Barnard, and H. L. Bonkovsky. "Inflammatory markers in chronic hepatitis C." Virchows Archiv 431, no. 3 (1997): 181–87. http://dx.doi.org/10.1007/s004280050086.
Full textFilipovich, O. M., and N. I. Kuznetzov. "Features of chronic hepatitis C course in pregnant women." Kazan medical journal 97, no. 5 (2016): 716–20. http://dx.doi.org/10.17750/kmj2016-716.
Full textDissertations / Theses on the topic "Hepatitis C chronic/pathology"
Pessôa, Mário Guimarães. ""Hepatite colestática associada ao vírus da hepatite C pós-transplante hepático: estudo virológico, histopatológico e imuno-histoquímico"." Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5144/tde-04042006-090453/.
Full textFollowing liver transplantation (OLT) HCV-related disease severity is highly variable, with a minority of cases progressing to an extremely severe form of cholestatic hepatitis, in which the pathogenesis is not yet understood. We aim to compare virological, histological and immunohistological changes in patients developing mild and severe post-OLT HCV recurrence. Twelve patients with recurrent HCV infection were studied (6 with severe and 6 with mild disease). Five HCV-infected immunocompetent patients were used as controls. We looked at viral load, quasispecies evolution of HCV, several histological parameters and immuno-reactivity of core antigens at three time-points (pre-OLT, early post-OLT and late post-OLT) as predictors of severity of recurrence post-OLT.
Zaver, Himesh, Momani Laith Al, Kalpit Devani, and Chakradhar M. Reddy. "Ledipasvir/sofosbuvir induced nephrotic syndrome: A challenging case of Hepatitis C management." Digital Commons @ East Tennessee State University, 2018. https://dc.etsu.edu/asrf/2018/schedule/80.
Full textPereira, Haydée Marina do Valle. "Características de pacientes com hepatite C crônica e transaminases normais." Universidade de São Paulo, 2005. http://www.teses.usp.br/teses/disponiveis/5/5134/tde-08102014-103411/.
Full textHepatitis C evolves progressively persisting in the majority of patients (85%) resulting in na asymptomatic chronic disease.Most patients have high ALT levels and approximately 25% normal ALT.The latter are usually female and there is no association between genotype and severity hepatic lesion.Histology shows small lesion and low amount of fibrosis, despite cirrhosis having been reported.Aiming at assessing prevalence, demographic, genotypical and anatomopathological characteristics in patients with normal ALT levels, we studied a series of 68 cases between January 1997 and April 2000.There was a prevalence of 13,82%, 45,6% of which were male and 54,4% female, average age of 38+/-13 years.Genotype 1 in 84,75%, 2 in 6,78% and 3 in 8,47%.In 52,9% of the cases revealed liver reaction, however, an important proportion of patients showed histologic signs of fibrosis (29%).Theses results suggest the need to revisit the algorithm for liver biopsy practice
Ribeiro, Maria de Fatima Gomes de Sá. ""Fatores prognósticos na evolução da hepatite C"." Universidade de São Paulo, 2005. http://www.teses.usp.br/teses/disponiveis/5/5144/tde-12082005-155039/.
Full textINTRODUCTION: The interaction of hepatitis C with alcohol consumption is thought to be a deleterious one. Progression of liver disease in chronic hepatits C depends on several other factors related to the host, virus and the enviroment but, these factors are not well understood yet. AIMS:To analyze demographic, epidemiological, biochemical and histopathological data of patients with hepatitis C according to heavy, light or no alcohol consumption.To assess the behavior of clinical, epidemiological and biochemical variables in relation to absent or mild histopathological alterations in contrast to severe alterations. METHODS: We have studied the demographic, epidemiological and laboratory data and then compared them to the histopathological alterations in 120 volunteer blood donors with hepatitis C virus divided into three groups according to alcohol intake: abstainers: n=41, light drinkers: n=36 and heavy drinkers: n=43. Liver histopathology alterations, namely architectural staging, periportal and lobular inflammation as well as portal inflammatory infiltrate were graded from 0 to 4 and afterwards divided into light (0 to 2) and severe (3 to 4). RESULTS: Almost 70% (83/120) of the patients were men and a high proportion of men (83.5 %) were drinkers (light and heavy). Women, on the other hand were more likely to be abstainers: 58.5% of them did not drink. Transfusion as risk factor for HCV was more frequent in abstainers (p= 0.056) whereas drug addiction predominated in heavy drinkers (p < 0.001). Regarding these groups no differences were found when duration of alcohol intake, abstinence of alcohol, surgery, other contamination factors, ALT, AST, GGT, degree of fibrosis, lobular inflammation and portal infiltrate were consider.Regarding three groups, mild periportal inflammation was significantly related with abstainers and light drinkers groups whereas severe periportal inflammation was more predominant in heavy drinkers (p=0.033). When we compared mild with severe histopathological alterations older age was significantly associated with severe fibrosis (p=0.004), periportal inflammation (p=0.001) and portal inflammatory infiltrate (p=0.001). Higher BMI values correlated significantly (p=0.013) with severe fibrosis whereas higher duration of alcohol intake was related to severe periportal inflammation (p=0.001). ALT level was significantly higher in severe fibrosis (p < 0.001), periportal inflammation (p=0.031) and lobular inflammation (p=0.013), whereas higher levels of AST correlated with severe fibrosis (p < 0.001), periportal inflammation (p < 0.001), lobular inflammation (p=0.001) and portal inflammatory infiltrate (p=0.018) . GGT values were significantly higher in severe fibrosis (p=0.012), periportal inflammation(p=0.013) and lobular activity (p=0.003) and higher levels of IgG correlated with fibrosis (p=0.040) and lobular inflammation (p=0.048). In the end, platelets were significantly lower (p < 0.001) in severe fibrosis and periportal inflammation (p=0.049). Logistic regression analysis identified AST and platelet count as independent predictors of severe fibrosis.CONCLUSIONS: Our study has shown a correlation between alcohol consumption and periportal inflammation, but not with fibrosis, which is correlated with age, high enzymes levels and low platelet count. AST and platelet count were the best predictors of severe fibrosis
Trepo, Eric. "Role of genetic factors in the progression of fibrosis in alcoholic liver disease and chronic hepatitis C." Doctoral thesis, Universite Libre de Bruxelles, 2012. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209659.
Full textLes travaux réalisés dans le cadre de cette thèse ont permis de montrer que :
1) Le CRS avait la capacité de prédire la progression de la fibrose chez des patients caucasiens ayant une HCC dans 2 cohortes européennes indépendantes.
2) Par ailleurs, dans la MAF, nous avons répliqué chez des patients caucasiens l’association entre le SNP rs738409 dans le gène PNPLA3 et la cirrhose. Nous avons également montré pour la première fois, que l’expression de PNPLA3 était significativement diminuée chez les patients avec une fibrose plus avancée. De plus, nous avons observé dans 2 cohortes européennes que rs738409 était également associé à la prévalence du CHC.
3) Enfin, nous avons également mis en évidence l’impact de ce même SNP sur la stéatose hépatique et la fibrose dans l’HCC sans toutefois qu’il influence la réponse à la thérapie antivirale dans 3 cohortes caucasiennes indépendantes.
Ainsi de manière remarquable, un même SNP (rs738409) apparait associé à des lésions hépatiques sévères dans les trois pathologies hépatiques chroniques les plus fréquentes (la MAF, l’HCC et la NAFLD). Ceci suggère des voies pathogéniques communes de la fibrogénèse hépatique. Par ailleurs, ces travaux soulignent indirectement que les GWAS ont la capacité d’ouvrir de nouvelles voies physiopathologiques et d’identifier de nouveaux variants, gènes ou région génétiques capables de constituer de nouveaux biomarqueurs et cibles thérapeutiques dans l’HCC et la MAF.
Doctorat en Sciences médicales
info:eu-repo/semantics/nonPublished
Deltenre, Pierre. "Hépatite C: contribution à l'évaluation de l'histoire naturelle et à la prise en charge thérapeutique de l'hépatite chronique." Doctoral thesis, Universite Libre de Bruxelles, 2012. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209708.
Full textLes travaux réalisés dans le cadre de cette thèse ont permis d’identifier des critères virologiques autorisant l’arrêt d’un traitement inefficace dès le terme de la 4ème semaine chez les malades présentant des transaminases normales et chez les malades non répondeurs à un premier traitement, de quantifier la perte de chance de réponse virologique lorsque la durée du traitement est limitée à 24 semaines chez les malades infectés par un génotype 1, d’évaluer la place de l’amantadine dans l’arsenal thérapeutique, de quantifier l’impact d’une insulino-résistance sur le taux de réponse virologique, de contribuer à l’élaboration d’une stratégie thérapeutique permettant une meilleure tolérance hématologique chez les malades hémodialysés et de quantifier l’impact des polymorphismes de l’interleukine 28B sur le taux réponse virologique des malades infectés par un génotype 2 ou 3. Nos travaux ont également permis de mesurer l’impact d’une consommation excessive d’alcool sur la morbi-mortalité liée au virus de l’hépatite C à l’échelle d’une population et de quantifier l’impact des mesures thérapeutiques actuelles et de stratégies thérapeutiques alternatives sur cette morbi-mortalité.
Au cours de la prochaine décennie, le traitement de l’hépatite chronique C sera articulé autour des molécules antivirales spécifiques agissant directement contre le virus de l’hépatite C. De nouvelles stratégies thérapeutiques intégrant la cinétique virale et les marqueurs génétiques prédictifs de la réponse virologique soutenue devront être élaborées afin d’offrir les meilleures chances d’éradication virologique au plus grand nombre de malades.
Doctorat en sciences médicales
info:eu-repo/semantics/nonPublished
Savage, Anne Kay. "The pathology of hepatitis C virus infection." Thesis, University College London (University of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.362544.
Full textLim, Teegan Reina. "Metabolic effects of hypoxia and chronic hepatitis C." Thesis, University of Birmingham, 2018. http://etheses.bham.ac.uk//id/eprint/8535/.
Full textChristie, John Michael Landale. "Viral persistence in hepatitis C virus infection." Thesis, University of Southampton, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268465.
Full textHAYASHI, HISAO, TOSHIKUNI TAKlKAWA, KATSUMI KATO, et al. "BIOCHEMICAL IMPROVEMENT OF CHRONIC HEPATITIS C AFTER GASTROINTESTINAL BLEEDING." Nagoya University School of Medicine, 1994. http://hdl.handle.net/2237/16077.
Full textBooks on the topic "Hepatitis C chronic/pathology"
Ozaras, Resat, and Dominique Salmon-Ceron, eds. Viral Hepatitis: Chronic Hepatitis C. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4.
Full textShiffman, Mitchell L., ed. Chronic Hepatitis C Virus. Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-1192-5.
Full textNational Digestive Diseases Information Clearinghouse (U.S.). Chronic hepatitis C: Current disease management. National Digestive Diseases Information Clearinghouse, 2006.
Dammacco, Franco. HCV Infection and Cryoglobulinemia. Springer-Verlag Italia, 2012.
Shih, Chiaho. Chronic hepatitis B and C: Basic science to clinical applications. World Scientific, 2012.
Foster, Graham. Management of Chronic Viral Hepatitis. Taylor & Francis Group Plc, 2004.
D, Goldin R., ed. Management of chronic viral hepatitis. Martin Dunitz, 2002.
San Francisco (Calif). Dept. of Public Health. Communicable Disease Control Unit. Chronic hepatitis B and hepatitis C infection surveillance report: 2009, San Francisco, California. San Francisco Department of Public Health, 2010.
San Francisco (Calif). Dept. of Public Health. Communicable Disease Control Unit. Chronic hepatitis B and hepatitis C infection surveillance report: 2010, San Francisco, California. San Francisco Department of Public Health, 2012.
Takahashi Memorial Forum (1995 Tokyo, Japan). Interferon therapy on chronic hepatitic C: Proceedings of the "Takahashi Memorial Forum", held in Tokyo, Japan on 25 November 1995. Edited by Takahashi Tadao 1908-, Yamanaka Masami, Okabe Kazuhiko, and Toda Gotaro. Elsevier, 1996.
Book chapters on the topic "Hepatitis C chronic/pathology"
Wight, D. G. D. "Chronic Hepatitis." In Atlas of Liver Pathology. Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-2212-2_7.
Full textTrabut, Jean Baptiste. "Chronic Hepatitis C." In Encyclopedia of Quality of Life and Well-Being Research. Springer Netherlands, 2014. http://dx.doi.org/10.1007/978-94-007-0753-5_365.
Full textAthwal, Varinder, and Martin Prince. "Chronic Hepatitis C." In In Clinical Practice. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43126-0_11.
Full textCohen, Stanley Martin. "Chronic Hepatitis C." In Liver Disease. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-98506-0_7.
Full textArends, Joop E., Maria Cristina Leoni, and Dominique Salmon-Ceron. "Acute Hepatitis C." In Viral Hepatitis: Chronic Hepatitis C. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_11.
Full textSun, Jiaren, Gaurav Chaturvedi, and Steven A. Weinman. "Viral Hepatitis C." In Molecular Pathology Library. Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-7107-4_38.
Full textDieterich, Douglas, Marie-Louise Vachon, and Damaris Carriero. "Hepatitis C in Special Populations." In Chronic Viral Hepatitis. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-565-7_4.
Full textForns, Xavier, and Jose M. Sánchez-Tapias. "Chronic viral hepatitis C." In Textbook of Clinical Gastroenterology and Hepatology. Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781118321386.ch81.
Full textOzaras, Resat, and Hakan Leblebicioglu. "Global Epidemiology of Chronic Hepatitis C Virus Infection." In Viral Hepatitis: Chronic Hepatitis C. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_1.
Full textKaraca, Çetin. "Extrahepatic Manifestations of Hepatitis C Virus Infection." In Viral Hepatitis: Chronic Hepatitis C. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_10.
Full textConference papers on the topic "Hepatitis C chronic/pathology"
Prasetia Nurwidda, Arvi Dian, Poernomo Boedi Setiawan, Iswan Abbas Nusi, et al. "Thrombocytopenia in Chronic Hepatitis C." In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007340404460452.
Full textKchir, H., D. KAFFEL, H. Dabbebi, et al. "AB1049 Rheumatological manifestations during chronic hepatitis c." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5886.
Full textNevkhoroshev, Yevhen, and Deonis Tkemaladze. "AUTOIMMUNE THYROIDITIS IN PATIENTS WITH CHRONIC HEPATITIS C." In TENDANCES SCIENTIFIQUES DE LA RECHERCHE FONDAMENTALE ET APPLIQUÉE, chair Lilia Bobro. European Scientific Platform, 2020. http://dx.doi.org/10.36074/30.10.2020.v2.07.
Full text"Secrum microRNA-122 with HCC in chronic hepatitis C." In 2018 International Conference on Medicine, Biology, Materials and Manufacturing. Francis Academic Press, 2018. http://dx.doi.org/10.25236/icmbmm.2018.63.
Full texthela, KCHIR, Ons Gharbi, Dhilel Issaoui, et al. "AB0529 SICCA SYNDROME DURING CHRONIC HEPATITIS C: PREVALENCE AND CHARACTERISTICS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7584.
Full textSchlevogt, B., K. Böker, S. Mauss, et al. "Weight gain after interferon-free clearance of chronic hepatitis C – Results from the German Hepatitis C-Registry (DHC-R)." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695343.
Full text"3.0T 1H MRS in Assessing the Steatosis in Chronic Hepatitis C Patients." In 2018 International Conference on Medicine, Biology, Materials and Manufacturing. Francis Academic Press, 2018. http://dx.doi.org/10.25236/icmbmm.2018.64.
Full textRuiz Gómez, A., L. Menéndez Naranjo, M. Sáez Garrido, et al. "5PSQ-033 Glecaprevir/pibrentasvir use in chronic hepatitis C: effectiveness and safety." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.350.
Full textIonescu, R. A., L. M. Pana, V. M. Pompilian, et al. "SAT0668 Articular involvement in chronic hepatitis c infection – a preliminary ultrasound study." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.7464.
Full textMa, Ling, YongSheng Yang, Xin Ge, YiDan Wan, and Xin Sang. "Prediction of disease progression of chronic hepatitis C based on XGBoost algorithm." In 2020 International Conference on Robots & Intelligent System (ICRIS). IEEE, 2020. http://dx.doi.org/10.1109/icris52159.2020.00151.
Full textReports on the topic "Hepatitis C chronic/pathology"
Kancheva, Lyudmila, Petar Nikolov, Tsvetelina Velikova, Ivan Valkov, Rossen Nikolov, and Lyudmila Mateva. Soluble CD14 is Associated with Disease Activity and Severity in Chronic Viral Hepatitis C and B. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, 2018. http://dx.doi.org/10.7546/crabs.2018.06.17.
Full textEvon, Donna, Jipcy Amador, Paul Stewart, et al. Changes in Health for Patients Who Complete Treatment for Chronic Hepatitis C Virus -- The PROP up TARGET Study. Patient-Centered Outcomes Research Institute® (PCORI), 2020. http://dx.doi.org/10.25302/06.2020.cer.140820660.
Full textXu, Yan, Yuyang Zhao, Yong Wang, et al. Concurrent hepatic steatosis increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B or C virus infection: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.7.0099.
Full text